https://www.selleckchem.com/pr....oducts/L-Adrenaline-
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been adopted as the standard of care for non-small cell lung cancer (NSCLC) patients harboring sensitizing mutations. Besides the two common mutations exon 19 deletion and L858R, which together comprise approximately 85% of mutations in NSCLC, rare mutations also exist, including point mutations, deletions, and insertions spanning exons 18-25. However, the responsiveness of uncommon mutations to EGFR TKIs remains elusive and attracts increasi
Like
Comment
Share
